Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (421-430 of 539) with videos related to

Pageof 54
Sort By:
Nature Communications|January 9, 2016
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myelomaDavid C Johnson, Niels Weinhold, Jonathan S Mitchell, et al.
Cancers|August 23, 2020
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD AssessmentKatharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, et al.
Cardio-Oncology (London, England)|July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trialLisa B Leypoldt, Linlin Guo, Britta Besemer, et al.
The New England Journal of Medicine|October 6, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Cell Reports|September 14, 2017
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer PolymorphismNi Li, David C Johnson, Niels Weinhold, et al.
BMC Cancer|May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaHans Salwender, Uta Bertsch, Katja Weisel, et al.
Leukemia|December 22, 2025
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myelomaMartin Grözinger, Muriel Schlanke, Jana Gröne, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Haematologica|August 8, 2015
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasoneMeletios A Dimopoulos, Katja C Weisel, Kevin W Song, et al.
Pageof 54

Showing results (421-430 of 539) with videos related to

Sort By:
Pageof 54
Nature Communications|January 9, 2016
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myelomaDavid C Johnson, Niels Weinhold, Jonathan S Mitchell, et al.
Cancers|August 23, 2020
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD AssessmentKatharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, et al.
Cardio-Oncology (London, England)|July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trialLisa B Leypoldt, Linlin Guo, Britta Besemer, et al.
The New England Journal of Medicine|October 6, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Cell Reports|September 14, 2017
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer PolymorphismNi Li, David C Johnson, Niels Weinhold, et al.
BMC Cancer|May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaHans Salwender, Uta Bertsch, Katja Weisel, et al.
Leukemia|December 22, 2025
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myelomaMartin Grözinger, Muriel Schlanke, Jana Gröne, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Haematologica|August 8, 2015
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasoneMeletios A Dimopoulos, Katja C Weisel, Kevin W Song, et al.
Pageof 54